Search

Bioga signs a collaboration agreement with BioM, one of Europe’s most influential clusters, to open new avenues of cooperation between the life sciences ecosystems of Galicia and Bavaria.

Positive clinical data presented at EHA for iadademstat in first line acute myeloid leukemia (AML); iadademstat+azacitidine+venetoclax resulted in 100% ORR, 89% CRc and 78% CR, including in patients

El traslado al PCB-UB sitúa la oficina de EBMT en un entorno plenamente alineado con su misión y su actividad. Barcelona se ha consolidado como uno de los principales polos europeos en ciencias de la

BIOMILK 7000 LAC enables lactose measurement in less than one minute at any point in the production process. AOAC certification confirms the reliability of BIOMILK 7000 LAC at the same level as

Between 27 and 36 million people in the European Union live with one of the 6,000 to 8,000 known rare diseases.

The Genomics for Universities Students (G4US) program is our commitment to supporting universities across Europe with flexible, scalable educational support—from curriculum feedback and hands-on

The conference programme will address the sector's major challenges, from advanced therapies and artificial intelligence to the bioeconomy and innovation financing.

Caixa Capital Risc, a CriteriaCaixa venture capital management company, rebrands to Criteria Capital Risc.

The future of medicine will depend not only on discovering new drugs, but also on developing technologies capable of delivering them more effectively. In this article, i+Med explains why encapsulation

Román Rodríguez González, Regional Minister for Education, Science, Universities and Vocational Training of the Xunta de Galicia, explores Galicia’s role as one of Europe’s most promising bioregions

Meet our new AseBio member, IGES Pharma. We spoke with Chus Castillo Gutiérrez, General Manager of the Barcelona Branch Office.

BIOSPAIN 2026 will provide the stage for Castilla y León to unveil a new approach to driving innovation in the life sciences.

AseBio believes the reform is moving in the right direction, while calling for regulatory ambition to be maintained throughout the negotiations in order to strengthen European innovation and

The largest funding rounds of 2025 were concentrated in companies that combine an unmet need, solid evidence, and the potential for international scaling.